Prothena Corporation plc

The Parkinson’s field is littered with clinical failures and another candidate, UCB’s minzasolmin, is the latest to fall in the quest for a disease modifying treatment. The Belgium-based group has i

S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, rai

Biopharma companies work hard to stack their pipelines with promising candidates. But which candidates are the most promising? A recent report from Evaluate finds that the top three pipeline assets

More mid-stage clinical trial failures are piling up in the Parkinson’s disease space, with the latest disappointment coming from South Korea's Bukwang Pharmaceutical Co., Ltd. , underlining the diff